Fig. 3From: An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspectiveHealthcare resource utilization costs at 18 months. ARTA, androgen receptor-targeted agent. The number correspond to a cohort of 100 patients for each treatmentBack to article page